Lymphoma: all 5,624 studies
Page 32 of 57. Open to participants first (824), then studies with results posted, then the rest; newest registration first within each.
- Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and SarcomasActive, not recruitingNCT03478462Phase 1
- Clinical Outcomes of Chronic Lymphocytic Leukemia (CCL) and Mantle Cell Lymphoma (MCL) Participants Treated With Ibrutinib: A Medical Chart Review From IndiaCompletedNCT03476655
- Brentuximab Vedotin as Alternative to the Autologous Stem Cell Transplantation in Relapsed and Refractory Classical Hodgkin's Lymphoma (BASALT)Status unknownNCT03474133Phase 2
- Unicentric Retrospective Analysis of a Cohort of 602 Young Adult and Adolescent Patients (AJA), Aged 15 to 30 Years, With Haematological Malignancies, and Managed Between 2000 and 2016CompletedNCT03469921
- Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory LymphomaStatus unknownNCT03468153Phase 1/2
- A Study of Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCLCompletedNCT03467373Phase 1
- Study of Roflumilast in Combination With Standard Chemotherapy for High-risk Diffuse Large B-cell LymphomaCompletedNCT03458546Phase 1
- Study of TQB2303 in Patients With Aggressive CD20 Positive Non-Hodgkin's LymphomaStatus unknownNCT03456466Phase 1/2
- Oral Azacitidine Plus Salvage Chemotherapy in Relapsed/Refractory Diffuse Large B Cell LymphomaCompletedNCT03450343Phase 1
- Pembrolizumab in Combination With Decitabine and Hypofractionated Index Lesion Radiation in Pediatrics and Young AdultsCompletedNCT03445858Early Phase 1
- Vinorelbine for Recurrent ALCL-2017CompletedNCT03443128Phase 2
- Patient-reported and Clinical Outcomes in Adults With Relapsed or Refractory Hodgkin's Lymphoma Receiving Brentuximab VedotinStatus unknownNCT03440788
- Avelumab in Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma[AVENT STUDY]Status unknownNCT03439501Phase 2
- Multi-antigen CMV-Modified Vaccinia Ankara Vaccine in Reducing CMV Related Complications in Patients With Blood Cancer Undergoing Donor Stem Cell TransplantWithdrawnNCT03438344Phase 2
- Long-term Follow-up Study for Patients Previously Treated With a Juno CAR T-Cell ProductTerminatedNCT03436771
- Chemokine Receptor CXCR4-targeting Molecular Imaging for Metabolic Characterization of Multiple Myeloma and LymphomaStatus unknownNCT03436342Early Phase 1
- Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP LossTerminatedNCT03435250Phase 1
- Direct Tumor Microinjection and FDG-PET in Testing Drug Sensitivity in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Stage IV Breast CancerTerminatedNCT03432741Phase 1
- A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical PracticeCompletedNCT03425591
- Study of STRO-001, an Anti-CD74 Antibody Drug Conjugate, in Patients With Advanced B-Cell MalignanciesCompletedNCT03424603Phase 1
- Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or LymphomaWithdrawnNCT03422874Phase 1
- Atezolizumab, Rituximab, Gemcitabine and Oxaliplatin in Patients With Relapsed or Refractory DLBCL Not Suitable for High-dose TherapyTerminatedNCT03422523Phase 2
- Safety, Tolerability, PK/PD of FE 203799 in Adults With LymphomasWithdrawnNCT03417765Phase 1/2
- Clinical Study of ET190L1 ARTEMIS™ in Relapsed, Refractory B Cell LymphomaCompletedNCT03415399Phase 1
- Evaluation of ClearLLab Leukemia and Lymphoma PanelsCompletedNCT03413644
- TLR9 Agonist SD-101, Anti-OX40 Antibody BMS 986178, and Radiation Therapy in Treating Patients With Low-Grade B-Cell Non-Hodgkin LymphomasCompletedNCT03410901Phase 1
- Chidamide for Patients With Relapse or Refractory Diffuse Large B-Cell Lymphoma and Follicular LymphomaStatus unknownNCT03410004Phase 2
- Social Media Listening in Improving Clinical Trial Recruitment in Patients With CancerWithdrawnNCT03408561Not applicable
- Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell LymphomaStatus unknownNCT03399747Phase 2
- Ibrutinib and Standard Immuno-Chemotherapy in Younger, High-Risk Patients With Diffuse Large B-Cell LymphomaCompletedNCT03399513Phase 2
- A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and LymphomaStatus unknownNCT03398967Phase 1/2
- Vinorelbine for Recurrent ACLCCompletedNCT03397953Phase 2
- CART-19 Cells for R/R B-cell LymphomaStatus unknownNCT03391726Phase 2/3
- A Trial Assessing the Effect of Pembrolizumab Combined with Radiotherapy in Patients with Relapsed, Refractory, Specified Stages of Cutaneous T-cell Lymphoma (CTCL) Mycosis Fungoides (MF)/Sezary Syndrome (SS)Active, not recruitingNCT03385226Phase 2
- Peptide Vaccination Against PD-L1 and PD-L2 in Relapsed Follicular LymphomaCompletedNCT03381768Phase 1
- Study of ET190L1 ARTEMIS™ T Cells in Relapsed and Refractory CD19+ Non-Hodgkin's LymphomaTerminatedNCT03379493Phase 1
- Apatinib for Relapsed and Refractory Diffuse Large B Cell LymphomaCompletedNCT03376958Phase 4
- Observational Study to Monitor Safety and Effectiveness of Obinutuzumab in Follicular Lymphoma or Previously Untreated Chronic Lymphocytic LeukemiaCompletedNCT03374137
- Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/LymphomaStatus unknownNCT03374007Phase 1
- Brentuximab Vedotin and Lenalidomide in Treating Patients With Relapsed or Refractory T-Cell LymphomasWithdrawnNCT03373305Phase 1
- Chidamide Combined With R-GDP in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)Status unknownNCT03373019Phase 2
- Phase III Study of SyB L-0501 in Combination With Rituximab to Treat Recurrent/Relapsed Diffuse Large B-Cell LymphomaCompletedNCT03372837Phase 3
- Phase 2 Study of Duvelisib in Previously Treated Patients With Chronic Lymphocytic Leukemia /Small Lymphocytic LymphomaWithdrawnNCT03370185Phase 2
- A Study of Atezolizumab in Combination With an Immunotherapy Agent Investigated With or Without Anti-Cd20 Therapy in Patients With Relapsed or Refractory Non-Hodgkin LymphomaWithdrawnNCT03369964Phase 1
- Lenalidomide Plus ICE in the Treatment of Refractory and Relapsed DLBCLStatus unknownNCT03367143Phase 2
- Nivolumab With Gemcitabine, Oxaliplatin + Rituximab in r/r Elderly Lymphoma PatientsCompletedNCT03366272Phase 2/3
- R-CHOP14 or R-CHOP21 &Consolidation PET-Oriented Radiotherapy (RT) in DLBCL PatientsCompletedNCT03364439Phase 2
- SHR-1210 in Patients With Relapsed or Refractory Extranodal NK/T Cell LymphomaStatus unknownNCT03363555Phase 2
- Pre-Screening Study to Identify MTAP Loss in Advanced Solid Tumors or LymphomaCompletedNCT03361358
- A Study to Evaluate the Effect of Food on the Pharmacokinetics (PK) of TAK-659 in Participants With Advanced Solid TumorWithdrawnNCT03359733Phase 1
- A Study of TAK-659 in Combination With Venetoclax for Adult Participants With Previously Treated Non-Hodgkin LymphomaCompletedNCT03357627Phase 1
- PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)TerminatedNCT03357224Phase 2
- Pralatrexate for Relapsed or Refractory Peripheral T-cell LymphomaCompletedNCT03356678
- Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT03355859Phase 1
- Romidepsin Versus Combination of Romidepsin Plus Pralatrexate in PTCLWithdrawnNCT03355768Phase 3
- A Phase I Study of Bendamustine and Melphalan Conditioning and Autologous Stem Cell Transplantation for Treatment of Multiple Myeloma and Relapsed/Refractory B-cell Lymphoma in Elderly PatientsActive, not recruitingNCT03352765Phase 1
- Idelalisib With Rituximab, Ifosfamide, Carboplatin, Etoposide (RICE) in Children and AdolescentsWithdrawnNCT03349346Phase 1
- Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLsStatus unknownNCT03346642Phase 1/2
- TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) for AutoSCT in LymphomaCompletedNCT03346096Phase 2
- Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT03344367Phase 1
- Treatment With Nivolumab at the Fixed Dose 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkins LymphomaCompletedNCT03343665Phase 1/2
- A Study of Safety and Efficacy of Nivolumab and Bendamustine (NB) in Patients With Relapsed/Refractory Hodgkin's LymphomaCompletedNCT03343652Phase 1/2
- Using a Novel Functional MRI Technique to Evaluate for NeurotoxicityCompletedNCT03342586
- A Study to Assess Mass Balance, Pharmacokinetics (PK), and Metabolism of Orally Administered [14 C]-TAK-659 in Participants With Advanced Solid Tumor and/or Lymphoma MalignanciesWithdrawnNCT03338881Phase 1
- ANIMATE: Phase II Study of Nivolumab Monotherapy for Relapsed/Refractory Hodgkin LymphomaActive, not recruitingNCT03337919Phase 2
- Application of Telemedicine to the Management of Aggressive LymphomasCompletedNCT03336138Not applicable
- Study of VTD in Waldenstrom's MacroglobulinemiaStatus unknownNCT03335098Phase 2
- B001 in Patients With CD20 Positive B-cell Non Hodgkin's LymphomaCompletedNCT03332121Phase 1
- A Phase II Study to Determine Pembrolizumab as Frontline Treatment of Patients With Hodgkin LymphomaActive, not recruitingNCT03331731Phase 2
- A Feasibility and Safety Study of Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ LeukemiaActive, not recruitingNCT03330691Phase 1
- A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced MalignanciesCompletedNCT03329950Phase 1
- Everolimus in Combination With Nelarabine, Cyclophosphamide and Etoposide in Lymphoblastic Leukemia/LymphomaCompletedNCT03328104Phase 1
- Use of Zarzio® in Post-autologous Stem Cell Transplantation ProcedureCompletedNCT03323541
- Chidamide Combined With PECM in Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL)Status unknownNCT03321890Phase 2
- Thalidomide Combined With R-CHOP in Newly Diagnosed，Untreated Double-expressor Diffuse Large B-Cell Lymphoma PatientsStatus unknownNCT03318835Phase 3
- Safety, Tolerability, Pharmacokinetics & Pharmacodynamics of Toripalimab for Patients With Recurrent Malignant LymphomaCompletedNCT03316144Phase 1
- BeEAC Conditioning Regimen in Malignant Lymphoma Subjects With Indications to Autologous Hematopoietic Stem-cell TransplantationStatus unknownNCT03315520Phase 2
- A Study of INCB050465 in Japanese Subjects With Previously Treated B-Cell Lymphoma (CITADEL-111)CompletedNCT03314922Phase 1
- Molecular Monitoring With Circulating Tumor DNA and Nivolumab MaintenanceCompletedNCT03311958Early Phase 1
- Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or LymphomasCompletedNCT03311412Phase 1
- A Combination of Rituximab and Varlilumab Immunotherapy in Patients with B-cell LymphomaCompletedNCT03307746Phase 1/2
- Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCLCompletedNCT03305445Phase 1
- Brentuximab Vedotin and Lenalidomide in Patients With Relapsed/ Refractory T-cell Lymphoma or Hodgkin LymphomaCompletedNCT03302728Phase 1
- A Study Evaluating Safety and Efficacy of C-CAR011 in Subjects With B-NHLStatus unknownNCT03299738Phase 1
- CD19 CAR and PD-1 Knockout Engineered T Cells for CD19 Positive Malignant B-cell Derived Leukemia and LymphomaStatus unknownNCT03298828Phase 1
- Minimal Residual Disease in Peripheral T-cell LymphomaCompletedNCT03297697
- A Study of PLX2853 in Advanced Malignancies.CompletedNCT03297424Phase 1
- The Study of Bendamustine, Rituximab, Ibrutinib, and Venetoclax in Relapsed, Refractory Mantle Cell LymphomaCompletedNCT03295240Early Phase 1
- Biomarker Driven Intensified ChemoImmunotherapy With Early CNS ProphylaxisActive, not recruitingNCT03293173Phase 2
- IACS-010759 in Advanced CancersCompletedNCT03291938Phase 1
- An Observational Study of MabThera Subcutaneous (SC) Safety in Participants With Non-Hodgkin's Lymphoma (NHL) or Chronic Lymphocytic Leukemia (CLL)CompletedNCT03289182
- Image-guided Lymphadanectomy in AMIGOTerminatedNCT03283423Not applicable
- Study of Safety and Efficacy of Avadomide (CC-122) Combined With RCHOP for Newly-diagnosed DLBCL With Poor Risk FactorsCompletedNCT03283202Phase 1
- Combination of Pembrolizumab With TGR-1202 in Patients With Relapsed/Refractory CLL and B-cell NHLActive, not recruitingNCT03283137Phase 1
- Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for LymphomaStatus unknownNCT03283111Not applicable
- Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory LymphomasCompletedNCT03276468Phase 2
- Chidamide With PET Regimen for Angioimmunoblastic T Cell Lymphoma (PET: Prednisone, Etoposide and Thalidomide)Status unknownNCT03273452Phase 2
- Phase 1 Study of IM156 in Patients With Advanced Solid Tumor and LymphomaCompletedNCT03272256Phase 1
- Immunotherapy With Bispecific CAR-T Cells for B-Cell Lymphoma, ALL and CLLStatus unknownNCT03271515Phase 1
- Chidamide With CHOP Regimen for de Novo PTCL Patients (CHOP: Cyclophosphamide, Etoposide, Vincristine and Prednisone; PTCL: Peripheral T Cell Lymphoma)Status unknownNCT03268889Not applicable